Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
•
Pulmonology
•
EGPA
•
Eosinophilic granulomatosis with polyangiitis
•
Asthma
Would you consider switching to benralizumab for patients with EGPA experiencing severe pulmonary symptoms despite being on mepolizumab?
Do you consider benralizumab for patients with EGPA with severe pulmonary symptoms on mepolizumab?
Related Questions
Do you utilize cytokine panels to guide treatment of patients with EGPA?
Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
How would you approach failure of maintenance therapy (Azathioprine) for PR3 positive, c-ANCA positive, pulmonary–renal vasculitis previously induced with cyclophosphamide, with a history of anaphylaxis to rituximab?
How do you determine which patients with ANCA associated vasculitis may be good candidates for reduced dose glucocorticoid tapering?
How long do you continue rituximab in patients with ANCA associated vasculitis who have achieved remission?
How do you treat IgA vasculitis with gastrointestinal involvement?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
How would you approach the workup of a female patient who has recurrent sinusitis with polyps (biopsy showed active and chronic inflammation) and myocarditis, but negative ANCA and normal eosinophil counts?
What is your approach to treating IgA nephropathy in patients who also have IgA vasculitis?